ClinicalTrials.gg
WithdrawnNCT05550363Updated Apr 3, 2024

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

A Phase 3 interventional study of Dexycu and Placebo/Vehicle in Cataract, sponsored by EyePoint Pharmaceuticals, Inc.. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Not currently pursuing indication

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
31st of 34
0 · median 50
Started
2022
with 5 others
Phase 3
9 of 34
1 open now
Registered
27th of 34
by date
Lead sponsor
3 of 34
EyePoint Pharmaceuticals, Inc.

Among the 34 studies testing dexamethasone in Cataract, this one is the 31st largest by enrollment, is one of 6 that started in 2022, is one of 9 in phase 3, and was the 27th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects at least 40 years of age scheduled for cataract surgery
  • Best corrected visual acuity (BCVA) of 20/30-20/200 in the study eye
  • Must be considered by the investigator to have visual (VA) acuity potential greater than 20/30 in the study eye.

Exclusion criteria

Exclusion Criteria:

  • Use of any within 7 days prior to Day 0
  • Injection of any corticosteroids, systemic immunomodulators or alkylating agents into any body tissue within 90 days
  • Score greater than "0" on the Ocular Pain Assessment in the study eye at Screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    DEXYCU

    DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg

    Drug: Dexycu

  • Placebo comparator
    Placebo

    Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg

    Other: Placebo/Vehicle

Interventions

  • DrugDexycu

    103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg

  • OtherPlacebo/Vehicle

    Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with absence of ocular pain (ie, score of '0') in the study eye at Day 8

    Time frame: Day 8

Secondary outcomes

  1. Proportion of subjects with absence of ocular pain in the study eye at Days 1, 3, 15, and 30

    Time frame: Days 1, 3, 15, and 30

  2. Mean ocular pain scores in the study eye

    Numerical Ocular Pain Scale from 0-10 with 0 being no pain and 10 being most severe

    Time frame: Days 1, 3, 15, and 30

  3. Proportion of subjects with absence of cells in the AC of the study eye

    Time frame: Days 1, 3, 15, and 30

  4. Proportion of subjects with absence of flare in the AC of the study eye

    Time frame: Days 1, 3, 15, and 30

  5. Mean AC cell score in the study eye

    AC count by Slit Lamp Biomicroscopy with 0 being none and 4 being most severe

    Time frame: Days 1, 3, 15, and 30

  6. Mean AC flare score in the study eye

    AC flare by Slit Lamp Biomicroscopy with 0 being absent and 4 being strong intensity

    Time frame: Days 1, 3, 15, and 30

  7. Rates of ocular (study eye and fellow eye) and non-ocular TEAEs

    Time frame: up to day 30

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2022; primary completion for Sep 2023, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 22, 2022
StartEst.
Sep 2022
Primary completionEst.
Sep 2023
CompletionEst.
Sep 2023
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05550363
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Sep 2022 (estimated)
Primary completion
Sep 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Apr 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion